Clinical Trials

If you would like more information on Hepatocellular and Cholangiocarcinoma Clinical Trials offered at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, please contact 1-877-LIVER99 (1-877-548-3799).

Current trial listing:

Hepatocellular Carcinoma

J17189- Phase Ib Study of Guadecitabine (SGI-110) and Durvalumab (MEDI 4736) in Patients with Advanced Hepatocellular Carcinoma, Pancreatic Adenocarcinoma, and Cholangiocarcinoma/Gallbladder Cancer
NCT03257761

J18118-The effect of CTLA4/PDL-1 Blockade following drug-eluting bead transarterial chemoembolization (DEB-TACE) in patients with intermediate stage of HCC using Durvalumab (MEDI4736) and Tremelimumab
NCT03638141

J1928-Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Toripalimab in Subjects with Advanced Malignancies (TAB001-01)

J17122-Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein binding PD-1 and LAG-3 in Patients with Unresectable or Metastatic Neoplasms (CP-MGD013-01)

Cholangiocarcinoma

J17159- A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Hyaluronan-High (HA-high) Subjects with Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
NCT03267940

J17189- Phase Ib Study of Guadecitabine (SGI-110) and Durvalumab (MEDI 4736) in Patients with Advanced Hepatocellular Carcinoma, Pancreatic Adenocarcinoma, and Cholangiocarcinoma/Gallbladder Cancer
NCT03257761

J18162  Study of Nivolumab and Cabiralizumab as neoadjuvant and adjuvant therapy for resectable biliary tract cancers.
NCT03768531

J18160- Phase 3 Study of Pemigatinib versus Gemcitabin plus Cisplatin in first-line treatment of Unresectable or Metastatic Cholangiocarcinoma
NCI03656536

J1926- Phase 2, Study to investigate the clinical efficacy of M7824 Monotherapy in locally advanced or metastatic biliary tract cancer who fail or are intolerant to first line Platinum based chemotherapy.
NCT03833661

J18164 Phase 2- A basket study of the oral selective pan-FGFR inhibitor Debio 1347 in subjects with solid tumors harboring a fusion of FGFR1, FGFR2 or FGFR3 (Debio 1347-201)

J1917  Phase 1- open label, first-in-human study of TR1801-ADC, an antibody drug conjugate (ADC), in patients with select solid tumors expressing c-Met (TR1801-CL-01)

Search For Cancer Clinical Trials